Trial Updates
10/16/25 — KESETT Materials Now Available
The following items have been added to the KESETT Workbench: Protocol V2 Modification Approval Notice (October 2025) EFIC Materials 2 (Focus Group Guide, CC Presentation) (October 2025) The following items have been added …
9/4/25 — New KESETT EFIC Materials
The following items are now available on the KESETT website under EFIC > EFIC Materials: KESETT Focus Group Invitation KESETT EFIC Trifold (Print in Actual Size) KESETT EFIC Flier IRB …
Several new resources have been added to the KESETT website. Please take a look at the following resources: Contact Emergency 24-Hour Study Hotline: 1-844-4KESETT (1-844-453-7388) EFIC CC Trifold CC-PD Language …
Overview
Ketamine add-on therapy for Established Status Epilepticus Treatment Trial (KESETT)
A multicenter, randomized, blinded study of treatment of patients with benzodiazepine-refractory status epilepticus in the emergency department, with either levetiracetam or levetiracetam combined with 1 mg/kg or 3 mg/kg dose ketamine to determine which treatment leads to more effective control of status epilepticus.
Contact
Emergency 24-Hour Study Hotline:
1-844-4KESETT (1-844-453-7388)
Education (training, website access, material development, technical support):
Courtney Miller ([email protected]) – Education Coordinator, or [email protected]
WebDCU Support (user account requests, technical support, CRF completion):
Riley Luckmann ([email protected]) (843) 792-1599
Morgan Davie ([email protected]) (843) 792-9201
Sara Meyer ([email protected]) (843) 792-1599
Project Manager:
Megan Wardius ([email protected]) 434-243-6768
Site Management & General Inquiries:
Vincent Cervantes ([email protected]) or [email protected]
Finances:
Valerie Stevenson ([email protected])